Biotech Values

[investorgold2002]

"by supporting NVS/MNTA’s argument to the District Court that NVS/MNTA’s generic does not infringe Teva’s Copaxone patents in the Orange Book. "


MNTA's copaxone patent is for characterizing and assuring the quality of Copaxone.

The patent claim(s) in trial here is "Lower molecular weight Copolymer is less toxic" .

So if Momenta produces such a lower molecular weight product, it is likely they will infringe on TEVA's patent.

Now since two other studies contradicted the above claim, it would have been possible that the patent itself be deemed invalid...but for that I guess they have to go through "inequitable conduct"...hmmm